InVera Medical Announced as Presenting Company at LSI Emerging Medtech Summit USA 2024

LSI USA 2024 Stephen Cox Emerging Medtech Summit Presenter

InVera Medical is gearing up for an exhilarating ride on the wave of innovation, and the excitement is building.

LSI Emerging Medtech Summit USA 2024 isn’t just a gathering; it’s becoming a rendezvous of brilliance, where innovative minds will collide, dreams will take flight, and InVera will pitch its heart out. As Mark Twain once wisely said, “The secret of getting ahead is getting started”. Well, here we are, on the brink of diving into the future of healthcare with gusto.

With investors to meet, friends to reunite with, and a tidal wave of enthusiasm propelling us forward, #LSIUSA2024 is about to transform Dana Point into the epicentre of healthcare innovation, one pitch at a time!

Read more via LinkedIn:  InVera Medical at LSI USA ’24 (LinkedIn)

*Investigational device not for sale in US or any international markets.

For more information please contact

Follow us on social media:



InVera Medical Seizes Momentum at JPM Healthcare Conference 2024, Anticipating a Year of Healthcare Transformation

The JPM Healthcare Conference 2024 in San Francisco (January 2024) proved to be an exhilarating experience for InVera Medical. The energy resonating throughout the event signals a positive shift in the air for the entire healthcare industry, with both investors and companies expressing optimism and projecting 2024 as a rebound year from the challenges of the past. The resurgence of buzz surrounding JPM week, coupled with recent spikes in M&A activity and anticipated interest rate reductions later this year, sets the stage for an exciting year ahead.

In the dynamic realm of healthcare, the call for innovation has never been clearer. The rise in chronic diseases and escalating healthcare costs amplify the urgency for transformative solutions. InVera Medical embraces this challenge head-on, gearing up for what promises to be a groundbreaking year in 2024.

InVera Medical is dedicated to driving innovation, fostering collaboration, and making a meaningful impact in venous disease in 2024 and beyond,” said Stephen Cox, CEO at InVera Medical. The company recognises the imperative need for groundbreaking solutions and is committed to addressing the pressing challenges in healthcare. “JP Morgan Healthcare conference week serves as a pivotal gathering for healthcare industry leaders, investors, and innovators. As part of InVera Medical’s strategic initiatives for the year, the conference has been the perfect platform to showcase our commitment to innovation and collaboration,” added Stephen.

InVera Medical warmly welcomed fellow attendees and potential investors with the Enterprise Ireland showcase during JPM2024 serving as a prime opportunity for InVera Medical to showcase its revolutionary efforts in transforming Chronic Venous Disease treatment. InVera Medical eagerly engaged in discussions, explored collaboration opportunities, and demonstrated its commitment to advancing healthcare.

Here’s to innovation, collaboration, and making a meaningful impact in healthcare in 2024 and beyond!

Read More via LinkedIn: InVera Medical at #JPM2024 (LinkedIn)

For more information please contact

Follow us on social media:



InVera Medical Announces Promotion of Dr. Aisling O’Sullivan to Vice President for Quality Assurance and Regulatory Affairs

Aisling O'Sullivan Headshot

InVera Medical, the developers of the InVera™ device – a less-invasive, effective, pain-free and faster minimally invasive endovenous medical device treatment for all chronic venous disease patients, proudly announce the promotion of Dr. Aisling O’Sullivan to the position of Vice President for Quality Assurance and Regulatory Affairs.

Aisling has been an invaluable asset to InVera Medical since joining the company in 2021. Her dedication, expertise, and commitment to ensuring the highest standards of quality and regulatory compliance have played a crucial role in the success and growth of the organisation.

In her new role, Aisling will lead the Quality Assurance and Regulatory Affairs teams, overseeing and enhancing processes to maintain and exceed industry standards. Her responsibilities will include developing and implementing strategies to ensure compliance with regulatory requirements, optimising quality management systems, and fostering a culture of continuous improvement throughout the organisation.

Commenting on the announcement, Stephen Cox, CEO, InVera Medical, stated, “We are thrilled to announce Aisling’s well-deserved promotion to Vice President for Quality Assurance and Regulatory Affairs. Her extensive experience and unwavering commitment to quality and compliance makes her the ideal leader for this critical role. We are confident that under her guidance, InVera Medical will continue to set the highest standards in the industry.”

With over 20 years’ experience navigating complex regulatory landscapes and implementing effective quality assurance measures, Aisling has led quality and regulatory teams, resulting in multiple new devices worldwide. Before joining InVera Medical, she held various positions at the National Standards Authority of Ireland, Omega Pharma, XBolt Orthopaedics, OrthoXel, Cook Medical, and RQM+. She holds a PhD in Microbiology from University College Cork, and a BSc Biotechnology from Dublin City University.

InVera Medical looks forward to continued success under Aisling’s leadership, reinforcing the company’s commitment to delivering innovative and high-quality healthcare solutions.

*Investigational device not for sale in US or any international markets.

For more information, please contact

Follow us on social media:



InVera Medical Launches Groundbreaking €4.6 million BioVAS DTIF Project: Pioneering Advances in Microvascular Vessel Intervention for Venous Leg Ulceration.

Disruptive Technologies Innovation Fund Government of Ireland Project Ireland 2040
Disruptive Technologies Innovation Fund Government of Ireland Project Ireland 2040

InVera Medical is thrilled to announce the official kick-off meeting for the BioVAS: Biological Micro-Surgical Vessel Advanced Closure System project, funded by the Disruptive Technology Innovation Fund (DTIF) Call 4 at InVera Medical HQ in ATU Innovation Hubs.

This pioneering €4.6 million consortium project, led by InVera Medical, will focus on the development of BioVAS – a microvascular vessel wall intervention specifically designed for treatment of venous leg ulceration. At its core the BioVAS project exemplifies industrial research, aiming to acquire new knowledge and skills that will significantly enhance the treatment of Venous Disease.

We’re honoured to collaborate with esteemed partners – Atlantic Technological University – MET Technology Gateway, University of Galway – NCLA – National Centre for Laser Applications, and ICS Medical Devices in this transformative initiative.

The Disruptive Technology Innovation Fund is a €500 million fund established under the National Development Plan (NDP) in 2018 by the Department of Enterprise, Trade and Employment with administrate support from Enterprise Ireland.
A sincere thank you to the Disruptive Technology Innovation Fund team for their invaluable support. Together with our consortium we are committed to making a lasting impact on Venous Leg Ulcer patient care.

Read more via LinkedIn:

For more information:

Consortium Lead: InVera Medical Email:

Project Partners: Atlantic Technological University – MET Technology Gateway | University of Galway – NCLA – National Centre for Laser Applications | ICS Medical Devices

“Investigational device not for sale in US or any international markets.”

Exciting News from InVera Medical at VEITH Symposium! (November 2023)

InVera Medical is honoured to participate in the prestigious VEITH Symposium in New York, an international gathering of leaders in vascular and endovascular surgery and a hub for ground-breaking advancements in the treatment of vascular disease. We’re thrilled to announce that Dr. Lowell Kabnick will feature the latest updates on our current clinical development pathway in session #70 titled “New Devices and Not Yet Approved” on Thursday, November 16, 2023, from 2:07 PM to 2:12 PM.

Join us for a glimpse into the future of venous disease treatment as we share the latest updates on our revolutionary technology. Discover the progress from our recent trials and our strategic plans for the journey ahead.

At InVera Medical, we’re committed to redefining the standards of care for Chronic Venous Disease, and events like VEITHsymposium provide a valuable platform to showcase our advancements and connect with fellow vascular innovators.

Stay tuned for more updates and insights as we continue our mission to make a meaningful impact in venous medicine!

Read more here:

*Investigational device not for sale in US or any international markets.

InVera Medical feature in the latest American Venous Forum | AVF Vein Specialist Newsletter on Emerging Technology

Vein Specialist

InVera Medical are delighted to feature in the latest American Venous Forum | AVF Vein Specialist Newsletter on Emerging Technology. We are excited to bring a mechanical-only venous ablation device to patients with Chronic Venous Disease.

A uniquely non-thermal, non-chemical and non-implant technology with massive potential to improve treatment outcomes.

Read more:

*Investigational device not for sale in US or any international markets

Key Opinion Leader Lowell Kabnick MD presents InVera Medical’s latest updates during the Emerging Technology and Global Abstracts sessions at UIP 2023.

InVera Medical had an amazing week at the International Union of Phlebology (UIP) 2023 meeting in Miami. Our CMO, Dr. Nigel Phelan, met with many leading experts at the forefront of venous disease treatments, gaining great clinical insights into the current treatment landscape. Special thanks to Lowell Kabnick MD for presenting our latest updates in the Emerging Technology and Global Abstracts sessions.

Read more about UIP 2023:

*Investigational device not for sale in US or any international markets

Nigel Phelan, CMO InVera Medical attends UIP 2023.

InVera Medical present at LSI Europe 23

InVera Medical at LSI Europe 2023
InVera Medical at LSI Europe 2023

InVera Medical had the incredible opportunity to attend the LSI Europe event in stunning Barcelona that combined the best of innovation with the pleasures of good food and wine.

We were overwhelmed by the high level of interest in our groundbreaking venous ablation treatment technology. It was a fantastic platform to connect with potential innovation partners and investors who share our passion for revolutionizing healthcare.

Read more:

*Investigational device not for sale in US or any international markets

InVera Medical named among Ireland’s breakthrough medical and life sciences innovators.

Ireland is home to indigenous inventors and innovators who are pushing the boundaries when it comes to medtech and life sciences.

Read about InVera Medical who are named among a number of examples of indigenous Irish healthcare, pharma, medtech and life sciences businesses with an export focus here:

*Investigational device not for sale in US or any international markets

InVera Medical awarded ISO 13485:2016 certification by BSI for the design, development, and manufacture of sterile ablation catheters for chronic venous disease.

ISO 13485 Certification

Recently, InVera Medical successfully attained the ISO 13485:2016 certification from BSI (British Standards Institution), an international notified body. ISO 13485 is an internationally recognised standard for quality management systems within the medical device industry. This achievement marks a crucial milestone preceding the market approval and registration of our InVera device in both the United States and Europe.

Expressing the significance of this accomplishment, Stephen Cox, CEO of InVera Medical remarked, “This certification is a testament to the culmination of years of dedicated effort, transforming our groundbreaking solution – the world’s first medical device to utilise the body’s biological response to treat varicose veins and venous ulcers without harmful side effects and translated that into an internationally recognised platform that is ready for manufacturing and human use”.

Aisling O’Sullivan, Director of Regulatory and Quality, played a pivotal role in initiating, developing, and executing the Quality Management System with the support of the InVera Medical team. Commenting on the announcement she emphasised, “ISO 13485:2016 certification establishes a robust foundation for the company to meet our customer requirements, ensure regulatory compliance, and foster excellence in day-to-day operational practices. Importantly, it represents a key step in delivering on our core values of patient safety.”  

We are thrilled that InVera Medical have been awarded the ISO 13485 qualification, affirming our commitment to maintaining a Quality Management System that consistently meets customer and regulatory standards throughout the InVera device’s lifecycle. With ISO 13485:2016 certification, the InVera Medical team will continue to increase its investment in quality management, delivering high-quality design, development, and manufacturing that not only meets but exceeds all specifications and regulatory requirements but makes product safety one of the company’s highest priorities.

*Investigational device not for sale in US or any international markets

InVera Medical CEO Stephen Cox joins “The Future of Medtech” panel at MedTech Strategist Innovation Summit Dublin 2023

What an incredible week at the MedTech Strategist Innovation Summit Dublin 2023!

It was great meeting investors and corporates who showed a lot of interest in our upcoming fundraise, and we received fantastic feedback on our latest progress and plans for the future. As always, there’s nothing quite like meeting people face-to-face to build long-lasting relationships.

During the main Medtech Strategist Innovation Summit event InVera Medical had the pleasure of participating in the “The Future of Medtech” panel hosted by Enterprise Ireland, where we discussed the latest advancements and trends in the industry with other innovative companies.

One of the interesting topics we discussed on the panel was the role of AI and machine learning in medtech, and ChatGPT’s potential in this area. As a language model trained on a vast amount of medical data, ChatGPT, AutoGPT, and other intelligent agent variants have the ability to assist medtech professionals in their decision-making processes and efficiencies as part of goals to improve patient outcomes.

However, it’s important to remember that while AI and machine learning can certainly enhance the field of medtech, they should never replace the human touch and expertise of innovation. It’s all about finding the right balance between technology and human interaction.

As Socrates once said, “To find yourself, think for yourself” and “I know one thing, that I know nothing.” In the ever-changing world of medtech, it’s important to keep an open mind and always be willing to learn and innovate.

We’re already looking forward to next year’s summit and the opportunity to continue collaborating with the amazing minds in our industry.

InVera Medical CEO, Stephen Cox presents at LSI USA (March 2023)

Stephen Cox, CEO InVera Medical, LSI USA 2023

InVera Medical is developing a catheter-based therapy for chronic venous disease. The device uses non-thermal energy to disrupt the inner vessel lining, resulting in natural scarring that diverts blood flow away from diseased vessels.

Watch Stephen’s pitch back here:

*Investigational device not for sale in US or any international markets